knowledge -WSS

knowledge

author：Wikipedia 2025-09-07 14:10:06 - browse：1

Vials and packaging for Leqembi, a new Alzheimer's medication approved in the U.S., but not yet in Europe. Illustration: Alex Hogan/STAT; Photo: Eisai via AP

LONDON — Starting Sunday, Alzheimer’s specialists will gather for a major conference in Amsterdam, convening at a time when the field, depending on which expert you ask, has some rare momentum behind it, with new therapies starting to show benefits for patients.

But despite the hard-won victories, the arrival of the new therapies presents a new set of challenges in Europe as countries plan for their possible rollouts, scientists and doctors told STAT.

Health systems will have to adapt to diagnose people earlier and monitor them for side effects associated with the treatments. If their medicines win European approval, companies will have to strike reimbursement deals in all member states, a process that often leaves some countries waiting years for new drugs to become available. The hurdles mean the therapies will likely be offered only at certain centers initially, constraining how many patients have access to them, doctors from across Europe said.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： BioMarin wins approval for gene therapy to treat hemophilia A
Next article： Readout LOUD podcast: ESMO highlights & Roivant's big deal

Wikipedia

WSS

FDA panel issues narrow recommendation for Covid vaccine booster doses

Readout Newsletter: Medeor's stem cell study, Moderna's stock dip

Anavex keeps shifting the goalposts in its clinical trials

Jack Smith previously got search warrant for Trump's Twitter, new court docs show

For Cytokinetics, FDA rejection of heart drug would help, not hinder

DeepMind touts AlphaFold's new skills as protein folding AI models face off

focus

knowledge

focus

Medical leaders decry Supreme Court decision on affirmative action

Brain injuries and the importance of a second opinion

As demand for Covid shots wanes, Moderna seeks its next success

A biotech analyst on neuroscience, placebo effect, not over

George Santos makes 1st court appearance after pleading not guilty to 13 counts

Methadone doses haven’t kept up in the age of fentanyl

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

DeepMind touts AlphaFold's new skills as protein folding AI models face off

Peter Hotez and the public health issue of online harassment

In Gaza, a nonprofit 3D prints tourniquets and stethoscopes

hotspot

DeepMind touts AlphaFold's new skills as protein folding AI models face off

How neuroscience research could help beat back brain cancer

Twitch streamer Kai Cenat speaks out for 1st time since causing mayhem with Union Square giveaway

How to convince healthy people to buy insurance

Key Senate panel to consider PBM, drug pricing reform package

Readout LOUD podcast: ESMO highlights & Roivant's big deal

focus

Wikipedia

Wikipedia

leisure time